EnerSys (ENS) · Oct 27, 2026 · Acquisition
$320M acquisition — $16.00 per share; approximately $320M enterprise value
EnerSys announced a $320M all-cash acquisition of Ultralife, expanding defense batteries and promising synergies before the deal closes in 2027.
EnerSys is reshaping itself around higher-value stored-energy applications, with its EnerGize framework emphasizing operational efficiency, defense, aerospace, domestic lithium production and selective strategic M&A. Its latest annual materials describe defense capability expansion through prior acquisitions, while management has maintained substantial balance-sheet flexibility for tuck-in deals.
This acquisition directly advances that strategy. EnerSys will buy Ultralife for $16.00 per share in cash, at an enterprise value of approximately $320 million, adding rechargeable and non-rechargeable batteries, battery systems and communications products serving military and specialized customers.
| Deal metric | Filing figure |
|---|---|
| Offer price | $16.00 per share (Transaction Details and Timing) |
| Enterprise value | Approximately $320 million (Transaction Details and Timing) |
| Ultralife fiscal 2025 revenue | $191 million (opening release paragraph) |
| Annual run-rate cost synergies | $15 million–$20 million within 18 months (opening release paragraph) |
| Supported Ultralife ownership | Approximately 40.3% (Tender and Support Agreement) |
| Expected closing | First quarter of calendar 2027 (Transaction Details and Timing) |
The strategic fit is more concrete than a generic defense pitch. Ultralife brings multi-chemistry battery capabilities, U.S.-based manufacturing capacity and products aimed at military communications, soldier power, drones, counter-drones and autonomous systems. That complements EnerSys’s ongoing push toward secure, FEOC-compliant domestic battery supply and its broader defense platform. 〔0〕
The financial case is meaningful but still mostly prospective. The stated $15 million to $20 million of annual run-rate synergies equates to roughly 8%–10% of Ultralife’s fiscal 2025 revenue, and EnerSys expects adjusted EPS accretion within approximately 18 months after closing. However, those benefits exclude transaction and integration costs, and the filing gives no purchase-accounting detail, standalone Ultralife profitability or quantified revenue-growth assumptions. 〔1〕
Execution risk is contained but not eliminated. EnerSys is paying with cash on hand and faces no financing condition; shareholders representing approximately 40.3% of Ultralife have agreed to tender, but that is below the more-than-50% minimum condition. Regulatory clearance in the United States, the United Kingdom and potentially other jurisdictions remains required, and EnerSys has not agreed to accept divestitures or other remedies. 〔2〕
Bottom line: This is a strategically coherent defense acquisition that strengthens EnerSys’s stated growth program and adds a credible synergy path, but the value creation remains contingent on closing and integration. The market knew EnerSys wanted selective M&A; the new information is the specific target, price and promised execution benefits—not yet realized earnings.
Tender offer commencement; expected Q1 2027 closing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!